リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry

吉本 武史 広島大学

2022.08.29

概要

BACKGROUND:
We determined the long-term event incidence among elderly patients with nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and oral anticoagulation.

METHODS:
Patients aged 75 years with documented nonvalvular atrial fibrillation enrolled in the prospective, multicenter, observational All Nippon Atrial Fibrillation in the Elderly Registry between October 2016 and January 2018 were divided into 2 groups according to history of stroke/TIA. The primary end point was the occurrence of stroke/systemic embolism within 2 years, and secondary end points were major bleeding and all-cause death within 2 years. Cox models were used to determine whether there was a difference in the hazard of each end point in patients with/without history of stroke/TIA, and in ischemic stroke/TIA survivors taking direct oral anticoagulants versus those taking warfarin.

RESULTS:
Of 32 275 evaluable patients (13 793 women [42.7%]; median age, 81.0 years), 7304 (22.6%) had a history of stroke/TIA. The patients with previous stroke/TIA were more likely to be male and older and had higher hazard rates of stroke/systemic embolism (adjusted hazard ratio, 2.25 [95% CI, 1.97–2.58]), major bleeding (1.25, 1.05–1.49), and all- cause death (1.13, 1.02–1.24) than the other groups. Of 6446 patients with prior ischemic stroke/TIA, 4393 (68.2%) were taking direct oral anticoagulants and 1668 (25.9%) were taking warfarin at enrollment. The risk of stroke/systemic embolism was comparable between these 2 groups (adjusted hazard ratio, 0.90 [95% CI, 0.71–1.14]), while the risk of major bleeding (0.67, 0.48–0.94), intracranial hemorrhage (0.57, 0.39–0.85), and cardiovascular death (0.71, 0.51–0.99) was lower among those taking direct oral anticoagulants.

CONCLUSIONS:
Patients aged 75 years with nonvalvular atrial fibrillation and previous stroke/TIA more commonly had subsequent ischemic and hemorrhagic events than those without previous stroke/TIA. Among patients with previous ischemic stroke/TIA, the risk of hemorrhagic events was lower in patients taking direct oral anticoagulants compared with warfarin.

Key Words:
atrial fibrillation , cardioembolism , direct oral anticoagulants , elderly , intracranial hemorrhage , stroke

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prog- nosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N. doi: 10.1016/s0002- 9149(98)00583-9

2. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–162. doi: 10.1016/S0140-6736(14)61774-8

3. McGrath ER, Kapral MK, Fang J, Eikelboom JW, Conghaile A, O’Conghaile A, Canavan M, O’Donnell MJ; Investigators of the Ontario Stroke Registry. Asso- ciation of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 2013;81:825–832. doi: 10.1212/WNL.0b013e3182a2cc15

4. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY Study Group. Dabigatran com- pared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157–1163. doi: 10.1016/S1474-4422(10)70274-X

5. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, et al.; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315–322. doi: 10.1016/S1474-4422(12)70042-X

6. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, et al.; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11:503–511. doi: 10.1016/S1474-4422(12)70092-3

7. Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, et al.; ENGAGE AF- TIMI 48 Investigators. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation- thrombolysis in myocardial infarction 48). Stroke. 2016;47:2075–2082. doi: 10.1161/STROKEAHA.116.013540

8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contribu- tor to stroke in the elderly. the Framingham study. Arch Intern Med. 1987;147:1561–1564. doi: 10.1001/archinte.1987.00370090041008

9. Okumura K, Yamashita T, Suzuki S, Akao M; J-ELD AF Investigators. A multi- center prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). Clin Cardiol. 2020;43:251–259. doi: 10.1002/clc.23294

10. Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, et al. Prospective observational study in elderly patients with non-valvular atrial fibrillation: rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. J Cardiol. 2018;72:300–306. doi: 10.1016/j.jjcc.2018.02.018

11. Kanemaru K, Yoshimoto T, Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, et al.; All Nippon Atrial Fibril- lation in the Elderly (ANAFIE) Group. Baseline characteristics of elderly Japanese patients aged 75 years with non-valvular atrial fibrillation and a history of stroke- ANAFIE registry. Circ J. 2020;84:516–523. doi: 10.1253/circj.CJ-19-0974

12. Koretsune Y, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, et al. Baseline demographics and clinical characteristics in the all nippon AF in the elderly (ANAFIE) registry. Circ J. 2019;83:1538–1545. doi: 10.1253/circj.CJ-19-0094

13. Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) registry. Eur Heart J Qual Care Clin Outcomes. 2021;8:202–213. doi: 10.1093/ehjqcco/qcab025

14. Yasaka M, Yamashita T, Akao M, Atarashi H, Ikeda T, Koretsune Y, Okumura K, Shimizu W, Tsutsui H, Toyoda K, et al. Background charac- teristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan. BMJ Open. 2021;11:e044501. doi: 10.1136/bmjopen-2020-044501

15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observa- tional Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577. doi: 10.7326/0003-4819-147-8-200710160-00010

16. Schulman S, Kearon C; Subcommittee on Control of Anticoagula- tion of the Scientific and Standardization Committee of the Inter- national Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal

17. Okada M, Inoue K, Tanaka N, Sakata Y, Akao M, Yamashita T, Suzuki S, Okumura K; J-ELD AF Investigators. Clinical outcomes of very elderly patients with atrial fibrillation receiving on-label doses of Apixaban: J-ELD AF registry subanalysis. J Am Heart Assoc. 2021;10:e021224. doi: 10.1161/JAHA.121.021224

18. Yamashita Y, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Clinical characteristics and outcomes in extreme elderly (age  85 years) japanese patients with atrial fibril- lation: the Fushimi AF registry. Chest. 2016;149:401–412. doi: 10.1378/chest.15-1095

19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864– 2870. doi: 10.1001/jama.285.22.2864

20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272. doi: 10.1378/chest.09-1584

21. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleed- ing in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100. doi: 10.1378/chest.10-0134

22. Ogawa H, Senoo K, An Y, Shantsila A, Shantsila E, Lane DA, Wolff A, Akao M, Lip GYH. Clinical features and prognosis in patients with atrial fibrillation and prior stroke: comparing the Fushimi and Darlington AF registries. EBio- Medicine. 2017;18:199–203. doi: 10.1016/j.ebiom.2017.03.022

23. Mazurek M, Shantsila E, Lane DA, Wolff A, Proietti M, Lip GYH. Second- ary versus primary stroke prevention in atrial fibrillation: insights from the Darlington atrial fibrillation registry. Stroke. 2017;48:2198–2205. doi: 10.1161/STROKEAHA.116.016146

24. Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, et al; SAMURAI Study Investiga- tors. Trends in oral anticoagulant choice for acute stroke patients with non- valvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836–842. doi: 10.1111/ijs.12452

25. Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibril- lation: a sub-analysis from the PREFER in AF (PREvention oF Thrombo- embolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6:e005657. doi: 10.1161/JAHA.117.005657

26. Senoo K, An Y, Ogawa H, Lane DA, Wolff A, Shantsila E, Akao M, Lip GY. Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. Heart. 2016;102:1878–1882. doi: 10.1136/heartjnl-2016-309741

27. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, et al; ROCKET AF Steer- ing Committee and Investigators. Efficacy and safety of rivaroxaban com- pared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138–146. doi: 10.1161/CIRCULATIONAHA.113.005008

28. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–1872. doi: 10.1093/eurheartj/ehu046

29. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5:e003432. doi: 10.1161/JAHA.116.003432

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る